CARMUSTINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C5H9Cl2N3O2
Molecular Weight	214.05
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

ClCCNC(=O)N(CCCl)N=O

InChI

InChIKey=DLGOEMSEDOSKAD-UHFFFAOYSA-N

InChI=1S/C5H9Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h1-4H2,(H,8,11)

HIDE SMILES / InChI

Molecular Formula	C5H9Cl2N3O2
Molecular Weight	214.05
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017422s046lbl.pdf
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/cdi/carmustine.html http://www.rxlist.com/bicnu-drug.htm http://www.wikidoc.org/index.php/Carmustine_(injection)

Carmustine is a cancer medication that interferes with the growth and spread of cancer cells in the body. Carmustine is used to treat brain tumors, Hodgkin's disease, multiple myeloma, and non-Hodgkin's lymphoma. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross-resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins. Pulmonary toxicity characterized by pulmonary infiltrates and/or fibrosis has been reported to occur from 9 days to 43 months after treatment with BiCNU and related nitrosoureas. A frequent and serious toxicity of BiCNU is delayed myelosuppression. Nausea and vomiting after intravenous administration of BiCNU are noted frequently. Greater myelotoxicity (e.g., leukopenia and neutropenia) has been reported when carmustine was combined with cimetidine.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
DNA 278 Target ID: CHEMBL2311221 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017422s046lbl.pdf \| http://www.drugbank.ca/drugs/DB00262	Inhibitor 8297	57.0 µM [IC50]
RNA 19 Target ID: CHEMBL2311222 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017422s046lbl.pdf \| http://www.drugbank.ca/drugs/DB00262	Inhibitor 8297
Glutathione reductase 11 Target ID: CHEMBL2755 Sources: http://www.drugbank.ca/drugs/DB00262 \| https://www.ncbi.nlm.nih.gov/pubmed/6623510 \| https://www.ncbi.nlm.nih.gov/pubmed/3806383 \| https://www.ncbi.nlm.nih.gov/pubmed/15321730	Inhibitor 8297	1.6 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Glioblastoma 65 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017422s046lbl.pdf	Primary	Approved 8429	BICNU Approved Use GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1) Launch Date 1977
Medulloblastoma 5 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017422s046lbl.pdf	Primary	Approved 8429	BICNU Approved Use GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1) Launch Date 1977
Astrocytoma 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017422s046lbl.pdf	Primary	Approved 8429	BICNU Approved Use GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1) Launch Date 1977
Ependymoma 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017422s046lbl.pdf	Primary	Approved 8429	BICNU Approved Use GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1) Launch Date 1977
Multiple myeloma 159 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017422s046lbl.pdf	Primary	Approved 8429	BICNU Approved Use GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1) Launch Date 1977
Hodgkin's lymphoma 34 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017422s046lbl.pdf	Secondary	Approved 8429	BICNU Approved Use GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1) Launch Date 1977
Non-Hodgkin's lymphoma 79 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017422s046lbl.pdf	Secondary	Approved 8429	BICNU Approved Use GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation, and recurrent glioblastoma multiforme as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade-malignant glioma as an adjunct to surgery and radiation (1) and recurrent glioblastoma multiforme as an adjunct to surgery (1) Launch Date 1977

C_max

Value	Dose	Co-administered	Analyte	Population
3.7 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/15077226	600 mg/m² 1 times / day steady-state, intravenous dose: 600 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: Cyclophosphamide \| Cisplatin	Cyclophosphamide \| Cisplatin	CARMUSTINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7.8 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3719578	1000 mg/m² single, intravenous dose: 1000 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:		CARMUSTINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
456 μg × min/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/15077226	600 mg/m² 1 times / day steady-state, intravenous dose: 600 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: Cyclophosphamide \| Cisplatin	Cyclophosphamide \| Cisplatin	CARMUSTINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
538 μM × min EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3719578	1000 mg/m² single, intravenous dose: 1000 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:		CARMUSTINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
18 min EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/15077226	600 mg/m² 1 times / day steady-state, intravenous dose: 600 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: Cyclophosphamide \| Cisplatin	Cyclophosphamide \| Cisplatin	CARMUSTINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
23% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3719578	1000 mg/m² single, intravenous dose: 1000 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:		CARMUSTINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
150 mg/m2 1 times / 7 weeks multiple, intravenous MTD Dose: 150 mg/m2, 1 times / 7 weeks Route: intravenous Route: multiple Dose: 150 mg/m2, 1 times / 7 weeks Co-administed with:: IFN-a, s.c(12 x 10(6) units/m2; Days 1-3 each week of a 7-week cycle.) Sources: https://pubmed.ncbi.nlm.nih.gov/9457812 Page: p.299, 300	unhealthy, 26-66 n = 11 Health Status: unhealthy Condition: Glioma Age Group: 26-66 Sex: M+F Population Size: 11 Sources: https://pubmed.ncbi.nlm.nih.gov/9457812 Page: p.299, 300	DLT: Leukopenia, Thrombocytopenia... Disc. AE: Pulmonary toxicity... Dose limiting toxicities: Leukopenia (grade 3-4, 45%) Thrombocytopenia (grade 3-4, 27%) AEs leading to discontinuation/dose reduction: Pulmonary toxicity (9%) Sources: https://pubmed.ncbi.nlm.nih.gov/9457812 Page: p.299, 300
125 mg/m2 1 times / 6 weeks multiple, intravenous MTD Dose: 125 mg/m2, 1 times / 6 weeks Route: intravenous Route: multiple Dose: 125 mg/m2, 1 times / 6 weeks Co-administed with:: streptozocin, i.v(2 g/m2, single) Sources: https://pubmed.ncbi.nlm.nih.gov/1531148 Page: p.258	unhealthy, 31-79 n = 24 Health Status: unhealthy Condition: Advanced cancer Age Group: 31-79 Sex: M+F Population Size: 24 Sources: https://pubmed.ncbi.nlm.nih.gov/1531148 Page: p.258	DLT: Thrombocytopenia... Disc. AE: Adult respiratory distress syndrome... Dose limiting toxicities: Thrombocytopenia (grade 3-4) AEs leading to discontinuation/dose reduction: Adult respiratory distress syndrome (grade 5, 4.2%) Sources: https://pubmed.ncbi.nlm.nih.gov/1531148 Page: p.258
200 mg/m2 1 times / 6 weeks multiple, intravenous (max) Recommended Dose: 200 mg/m2, 1 times / 6 weeks Route: intravenous Route: multiple Dose: 200 mg/m2, 1 times / 6 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Brain tumors\| Multiple myeloma\| Hodgkin's lymphoma\| Non-Hodgkin's lymphomas Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1	Disc. AE: Marrow depression of, Thrombocytopenia... AEs leading to discontinuation/dose reduction: Marrow depression of Thrombocytopenia Leukopenia Pulmonary toxicity Administration site extravasation Carcinogenicity Fetal damage Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1

AEs

AE	Significance	Dose	Population
Pulmonary toxicity	9% Disc. AE	150 mg/m2 1 times / 7 weeks multiple, intravenous MTD Dose: 150 mg/m2, 1 times / 7 weeks Route: intravenous Route: multiple Dose: 150 mg/m2, 1 times / 7 weeks Co-administed with:: IFN-a, s.c(12 x 10(6) units/m2; Days 1-3 each week of a 7-week cycle.) Sources: https://pubmed.ncbi.nlm.nih.gov/9457812 Page: p.299, 300	unhealthy, 26-66 n = 11 Health Status: unhealthy Condition: Glioma Age Group: 26-66 Sex: M+F Population Size: 11 Sources: https://pubmed.ncbi.nlm.nih.gov/9457812 Page: p.299, 300
Thrombocytopenia	grade 3-4, 27% DLT	150 mg/m2 1 times / 7 weeks multiple, intravenous MTD Dose: 150 mg/m2, 1 times / 7 weeks Route: intravenous Route: multiple Dose: 150 mg/m2, 1 times / 7 weeks Co-administed with:: IFN-a, s.c(12 x 10(6) units/m2; Days 1-3 each week of a 7-week cycle.) Sources: https://pubmed.ncbi.nlm.nih.gov/9457812 Page: p.299, 300	unhealthy, 26-66 n = 11 Health Status: unhealthy Condition: Glioma Age Group: 26-66 Sex: M+F Population Size: 11 Sources: https://pubmed.ncbi.nlm.nih.gov/9457812 Page: p.299, 300
Leukopenia	grade 3-4, 45% DLT	150 mg/m2 1 times / 7 weeks multiple, intravenous MTD Dose: 150 mg/m2, 1 times / 7 weeks Route: intravenous Route: multiple Dose: 150 mg/m2, 1 times / 7 weeks Co-administed with:: IFN-a, s.c(12 x 10(6) units/m2; Days 1-3 each week of a 7-week cycle.) Sources: https://pubmed.ncbi.nlm.nih.gov/9457812 Page: p.299, 300	unhealthy, 26-66 n = 11 Health Status: unhealthy Condition: Glioma Age Group: 26-66 Sex: M+F Population Size: 11 Sources: https://pubmed.ncbi.nlm.nih.gov/9457812 Page: p.299, 300
Thrombocytopenia	grade 3-4 DLT	125 mg/m2 1 times / 6 weeks multiple, intravenous MTD Dose: 125 mg/m2, 1 times / 6 weeks Route: intravenous Route: multiple Dose: 125 mg/m2, 1 times / 6 weeks Co-administed with:: streptozocin, i.v(2 g/m2, single) Sources: https://pubmed.ncbi.nlm.nih.gov/1531148 Page: p.258	unhealthy, 31-79 n = 24 Health Status: unhealthy Condition: Advanced cancer Age Group: 31-79 Sex: M+F Population Size: 24 Sources: https://pubmed.ncbi.nlm.nih.gov/1531148 Page: p.258
Adult respiratory distress syndrome	grade 5, 4.2% Disc. AE	125 mg/m2 1 times / 6 weeks multiple, intravenous MTD Dose: 125 mg/m2, 1 times / 6 weeks Route: intravenous Route: multiple Dose: 125 mg/m2, 1 times / 6 weeks Co-administed with:: streptozocin, i.v(2 g/m2, single) Sources: https://pubmed.ncbi.nlm.nih.gov/1531148 Page: p.258	unhealthy, 31-79 n = 24 Health Status: unhealthy Condition: Advanced cancer Age Group: 31-79 Sex: M+F Population Size: 24 Sources: https://pubmed.ncbi.nlm.nih.gov/1531148 Page: p.258
Administration site extravasation	Disc. AE	200 mg/m2 1 times / 6 weeks multiple, intravenous (max) Recommended Dose: 200 mg/m2, 1 times / 6 weeks Route: intravenous Route: multiple Dose: 200 mg/m2, 1 times / 6 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Brain tumors\| Multiple myeloma\| Hodgkin's lymphoma\| Non-Hodgkin's lymphomas Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1
Carcinogenicity	Disc. AE	200 mg/m2 1 times / 6 weeks multiple, intravenous (max) Recommended Dose: 200 mg/m2, 1 times / 6 weeks Route: intravenous Route: multiple Dose: 200 mg/m2, 1 times / 6 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Brain tumors\| Multiple myeloma\| Hodgkin's lymphoma\| Non-Hodgkin's lymphomas Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1
Fetal damage	Disc. AE	200 mg/m2 1 times / 6 weeks multiple, intravenous (max) Recommended Dose: 200 mg/m2, 1 times / 6 weeks Route: intravenous Route: multiple Dose: 200 mg/m2, 1 times / 6 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Brain tumors\| Multiple myeloma\| Hodgkin's lymphoma\| Non-Hodgkin's lymphomas Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1
Leukopenia	Disc. AE	200 mg/m2 1 times / 6 weeks multiple, intravenous (max) Recommended Dose: 200 mg/m2, 1 times / 6 weeks Route: intravenous Route: multiple Dose: 200 mg/m2, 1 times / 6 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Brain tumors\| Multiple myeloma\| Hodgkin's lymphoma\| Non-Hodgkin's lymphomas Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1
Marrow depression of	Disc. AE	200 mg/m2 1 times / 6 weeks multiple, intravenous (max) Recommended Dose: 200 mg/m2, 1 times / 6 weeks Route: intravenous Route: multiple Dose: 200 mg/m2, 1 times / 6 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Brain tumors\| Multiple myeloma\| Hodgkin's lymphoma\| Non-Hodgkin's lymphomas Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1
Pulmonary toxicity	Disc. AE	200 mg/m2 1 times / 6 weeks multiple, intravenous (max) Recommended Dose: 200 mg/m2, 1 times / 6 weeks Route: intravenous Route: multiple Dose: 200 mg/m2, 1 times / 6 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Brain tumors\| Multiple myeloma\| Hodgkin's lymphoma\| Non-Hodgkin's lymphomas Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1
Thrombocytopenia	Disc. AE	200 mg/m2 1 times / 6 weeks multiple, intravenous (max) Recommended Dose: 200 mg/m2, 1 times / 6 weeks Route: intravenous Route: multiple Dose: 200 mg/m2, 1 times / 6 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Brain tumors\| Multiple myeloma\| Hodgkin's lymphoma\| Non-Hodgkin's lymphomas Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf Page: p.1

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3423	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3423
ChemicalBook	CB0449612	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0449612
MolPort	MolPort-003-665-505	https://www.molport.com/shop/molecule-link/MolPort-003-665-505
ZINC	ZINC000003830387	http://zinc15.docking.org/substances/ZINC000003830387
eMolecules	535644	https://www.emolecules.com/cgi-bin/more?vid=535644

PubMed

Title	Date	PubMed
Cytoprotective effects of trimetazidine in carmustine cholestasis.	1999 Jul	10445391
Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule.	1999 Jun	10455409
Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy.	2000 Sep	11020424
High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience.	2001	11400952
Inhaled steroids as prophylaxis for delayed pulmonary toxicity syndrome in breast cancer patients undergoing high-dose chemotherapy and autologous stem cell transplantation.	2001	11400949
High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults.	2001	11291555
High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin's disease: atopy predicts idiopathic diffuse lung injury syndromes.	2001	11215699
Inducible nitric oxide synthase neutralizes carbamoylating potential of 1,3-bis(2-chloroethyl)-1-nitrosourea in c6 glioma cells.	2001 Apr	11259558
The role of glutathione reductase in the cytotoxicity of chromium (VI) in isolated rat hepatocytes.	2001 Apr 16	11311213
Temozolomide in combination with other cytotoxic agents.	2001 Aug	11550136
Bcl-2 overexpression decreases BCNU sensitivity of a human glioblastoma line through enhancement of catalase activity.	2001 Aug 21-Sep 5	11596115
Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation.	2001 Dec	11751525
HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation.	2001 Dec	11751494
Induction of lacI mutations in Big Blue Rat-2 cells treated with 1-(2-hydroxyethyl)-1-nitrosourea: a model system for the analysis of mutagenic potential of the hydroxyethyl adducts produced by 1,3-bis (2-chloroethyl)-1-nitrosourea.	2001 Dec 12	11733074
Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).	2001 Feb	11426523
Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.	2001 Feb	11234899
Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia.	2001 Feb 15	11181679
Antitumor efficacy of SarCNU in a human glioma xenograft model expressing both MGMT and extraneuronal monoamine transporter.	2001 Jan	11349876
Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study.	2001 Jan 3	11136838
Amifostine does not protect malignant lymphoma cell lines from the cytotoxic effects of various chemotherapeutics in vitro.	2001 Jul	11699416
Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?	2001 Jul	11529465
A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma.	2001 Jul 15	11466698
Protection of mammalian cells against chemotherapeutic agents thiotepa, 1,3-N,N'-bis(2-chloroethyl)-N-nitrosourea, and mafosfamide using the DNA base excision repair genes Fpg and alpha-hOgg1: implications for protective gene therapy applications.	2001 Mar	11181913
The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.	2001 Mar 1	11229338
Long-term results of a phase-II-pilot trial on preoperative high-dose chemotherapy with stem cell rescue in patients with cancer of the upper gastrointestinal tract.	2001 Mar-Apr	11182052
Immunoablative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis.	2001 May	11377494
Comparison of single- versus double-bolus treatments of O(6)-benzylguanine for depletion of O(6)-methylguanine DNA methyltransferase (MGMT) activity in vivo: development of a novel fluorometric oligonucleotide assay for measurement of MGMT activity.	2001 May	11303039
Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.	2001 Nov 15	11698273
Outcome and long-term side effects after synchronous radiochemotherapy for childhood brain stem gliomas.	2001 Oct	11694794
Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.	2001 Oct	11595684
Levels of N7-(2-hydroxyethyl)guanine as a molecular dosimeter of drug delivery to human brain tumors.	2001 Oct	11584893
The effectiveness of the O(6)-alkylguanine-DNA alkyltransferase encoded by the ogt(ST) gene from S. typhimurium in protection against alkylating drugs, resistance to O(6)-benzylguanine and sensitisation to dibromoalkane genotoxicity.	2001 Oct 18	11525913
[Autograft and multiple myeloma: experience of the Intergroupe Français du Myélome].	2001 Sep	11604362
Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs.	2001 Sep	11592341
Nitric oxide and free stable nitroxyl radicals in the mechanism of biological action of the spin-labeled compounds.	2001 Sep	11516220
Use of pure t-butanol as a solvent for freeze-drying: a case study.	2001 Sep 11	11532568
Up-regulation of K(+) channels in diabetic rat ventricular myocytes by insulin and glutathione.	2002 Jan	11744015
Escherichia coli FPG and human OGG1 reduce DNA damage and cytotoxicity by BCNU in human lung cells.	2002 Jan	11741815

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose of BiCNU as a single agent in previously untreated patients is 150 to 200 mg/m2 intravenously every 6 weeks. This may be given as a single dose or divided into daily injections such as 75 to 100 mg/m2 on 2 successive days.

Route of Administration: Other

In Vitro Use Guide

LD50 values for the short term glioma tumour cultures lay in the range 10 - 90 μg/ml for Carmustine.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:02:18 GMT 2023` Edited by `admin` on `Fri Dec 15 15:02:18 GMT 2023`
Record UNII	U68WG3173Y
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CARMUSTINE

Official Name

English

CARMUSTINE [EP IMPURITY]

Common Name

English

GLIADEL

Brand Name

English

SRI-1720

Code

English

BISCHLOROETHYL NITROSOUREA [IARC]

Common Name

English

CARMUSTINE [JAN]

Common Name

English

Carmustine [WHO-DD]

Common Name

English

DTI-015

Code

English

CARMUSTINE [EP MONOGRAPH]

Common Name

English

SK-27702

Code

English

CARMUSTINE [MI]

Common Name

English

carmustine [INN]

Common Name

English

CARMUSTINE [USAN]

Common Name

English

CARMUSTINE [MART.]

Common Name

English

UREA, N,N'-BIS(2-CHLOROETHYL)-N-NITROSO-

Systematic Name

English

CARMUSTINE [USP MONOGRAPH]

Common Name

English

CAMUSTINE [VANDF]

Common Name

English

CARMUSTINE [HSDB]

Common Name

English

BICNU

Brand Name

English

CARMUBRIS

Brand Name

English

NSC-409962

Code

English

FDA-0345

Code

English

BCNU

Code

English

CARMUSTINE [USP-RS]

Common Name

English

BECENUN

Brand Name

English

CARMUSTINE [ORANGE BOOK]

Common Name

English

1,3-Bis(2-chloroethyl)-1-nitrosourea

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C699